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One sentence summary 
This study identifies a reproducible, objective, biobehavioral phenotype within the 
broader clinical syndrome of PTSD, which characterizes a patient subgroup that fails to 
respond to the best-supported treatment, and is associated with specific impairments in 
neurostimulation-evoked neural signal flow.  
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Abstract 
 
A mechanistic understanding of psychopathology has been hampered by extensive 
heterogeneity of biology, symptoms, and behavior within subjectively-defined diagnostic 
categories. We investigated whether leveraging individual differences in core 
information processing impairments associated with post-traumatic stress disorder 
(PTSD) patients could reveal biophenotypes within the disorder that are clinically- and 
mechanistically-relevant. We found that a subgroup of PTSD patients from two 
independent cohorts displayed both aberrant functional connectivity within the ventral 
attention network (VAN) and impaired verbal memory – despite the substantial 
clinical/demographic differences between the cohorts. This combined phenotype was 
not associated with differences in current symptoms or comorbidities, but nonetheless 
predicted resistance to psychotherapy, the best-validated treatment for PTSD. Using 
concurrent focal non-invasive transcranial magnetic stimulation (TMS) and 
electroencephalography we then identified alterations in neural signal flow in the VAN 
evoked by direct stimulation of that network that were associated with these individual 
differences in within-VAN functional connectivity. Our findings thus leverage objective 
neurobiological mechanisms to define an otherwise clinically-latent but prognostically-
relevant phenotype within the broader clinical syndrome of PTSD. This approach 
promotes a transition from a purely descriptive characterization of psychopathology to 
one with enhanced inferential power by virtue of direct perturbation of circuit dynamics, 
which directly inform targets for remediation through plasticity-inducing brain stimulation 
treatments. 
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Introduction 
 
Extreme stress can exert long-lasting detrimental effects and is a precipitant of 
numerous manifestations of psychopathology in humans. The most severe of these is 
post-traumatic stress disorder (PTSD), a common, chronic and disabling mental illness 
whose pathophysiology is both complex and poorly understood. PTSD, like all 
psychiatric disorders, is currently diagnosed based on different combinations of clinical 
symptoms (1, 2). As a consequence of this symptom-based diagnostic framework, the 
syndrome of PTSD contains extensive clinical heterogeneity, covering hundreds of 
thousands of different symptom combinations (3-5). Moreover, despite many years of 
pioneering work characterizing the brains, behavior and physiology of individuals with 
PTSD, we still lack biological metrics for consistently partitioning clinical variation within 
the broad clinical syndrome of PTSD in a way that has both mechanistic implications for 
understanding disorder expression as well as demonstrable clinical relevance for the 
practitioner. Establishment of such metrics could provide a basis for targeted treatment 
selection and development of novel therapeutics, much as has been achieved in other 
areas of biology and medicine (6). 
Our approach draws on the premise that disruption in basic brain information-
processing functions underlying cognition form the foundation upon which various 
aspects of PTSD are built. For example, impaired declarative memory in PTSD, most 
evident for verbal learning and memory (7), may contribute to development of perturbed 
emotional memories acquired as a result of PTSD-producing traumas (8, 9), and is 
relevant for treatment outcome (7, 9-12). Memory intrusions are a classic PTSD 
symptom and memory is a primary target for evidence-based treatments utilizing 
therapeutic exposure. Similarly, impairments in attention and higher-level executive 
functions may result in difficulty disengaging from trauma-relevant stimuli and engaging 
with the task at hand (13). Moreover, we expect that since only some PTSD patients 
display impaired cognition when compared with healthy individuals, the associated 
neural abnormalities will likewise be evident in only a portion of patients. As such, 
cognitive deficits may allow us to understand clinically-meaningful heterogeneity in 
PTSD by providing an opportunity to link dysfunction(s) in core brain processes to the 
neurobiology of information-processing systems (10), and from there to account for 
heterogeneity in symptoms or treatment outcome.  
At the neural level, widespread interactions within and across distributed brain 
networks are well-documented to underlie cognitive processes (14-19). Individual 
differences in cognitive capacities have in turn been related to individual differences in 
connectivity of the fronto-parietal, default-mode, dorsal attention and ventral attention 
(i.e. “salience”) networks using functional magnetic resonance imaging (fMRI), even 
under task-free resting-state conditions in healthy individuals (20, 21). Neuroimaging 
studies in PTSD have also identified resting-state fMRI connectivity abnormalities in 
these large-scale neural networks in individuals with PTSD (22-24). As a clinical 
biomarker tool, resting-state connectivity carries additional advantages, such as its ease 
of semi-standardized acquisition and independence of performance requirements. Thus, 
examining deficits in cognition and related resting-state network interactions may help 
objectively define clinically-relevant phenotypes within the larger clinical syndrome of 
PTSD. This would further ground aspects of clinical heterogeneity in biological 
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mechanisms. Additionally, use of resting-state connectivity facilitates generalization of 
our findings given that collection of these data is now commonplace in semi-
standardized ways across human imaging studies. 
Resting-state connectivity has been a major area of biomarker-related research 
because it has been presumed that abnormalities in resting-state fMRI connectivity 
reflect alterations in the interaction between different brain regions (i.e. in direct 
information flow)(25). However, due to the limitations of conventional neuroimaging with 
respect to causal inference, the relationship between identified abnormalities in network 
interactions in patients (e.g. using resting-state fMRI) and affected components of 
neural signal flow mechanisms has remained largely unknown. Not only is this 
knowledge important for understanding the meaning of resting-state fMRI connectivity, 
but also for driving a transition from a descriptive approach to mental illness to a circuit-
based mechanistic one that could also be used to directly guide much-needed novel 
interventions (26). One way to address this challenge is to directly and non-invasively 
stimulate cortical regions using single pulses of transcranial magnetic stimulation 
(spTMS) while recording consequent brain activity with electroencephalography (EEG), 
thereby allowing interrogation of stimulation-evoked neural signal flow at a neural 
temporal scale (27-31). Each TMS pulse produces a series of EEG responses. Early 
phase-locked potentials (e.g. at 30ms) likely reflect evoked excitatory activity, while later 
potentials (~50-400ms) likely reflect a slow inhibitory rebound to stimulation unfolding 
over several hundred milliseconds (30, 32-35). Changes in oscillatory power can outlast 
the phase-locked potentials, for which inhibitory processes have also been implicated 
(36). By stimulating various cortical regions with concurrent spTMS/EEG one can 
therefore relate stimulation-driven effects on signal flow to differences in fMRI 
connectivity, thus grounding our understanding of fMRI connectivity in more specific 
neurophysiological mechanisms using non-invasive neurostimulation. As such, not only 
does concurrent spTMS/EEG offer an opportunity to understand how direct stimulation-
evoked neural signal flow is associated with fMRI connectivity, but it also establishes 
brain loci and neurophysiological signals that may in turn become targets for 
remediation through plasticity-inducing repetitive TMS-based treatment.  
In the current study we therefore investigated the biology underlying 
heterogeneity within the broader PTSD clinical syndrome by: 1) identifying how deficits 
in basic cognitive functioning relate to abnormalities in resting-state fMRI connectivity in 
cognitive networks, thereby facilitating broad and maximally-generalizable inference 
regarding aspects of network function underlying information-processing dysfunction; 2) 
testing whether phenotypes defined through cognition and network connectivity 
generalize across demographically and clinically-distinct PTSD populations, 3) 
delineating the clinical relevance of these phenotypes by examining their relationship to 
both individual differences in symptom expression as well as individual differences in 
capacity to benefit from evidence-based treatment, and 4) interrogating alterations in 
neurostimulation-evoked neural signal flow using concurrent spTMS/EEG, which may 
underlie and help explain individual differences in network biophenotypes. Figure 1 
shows an overview of the experimental design. 
 
Results 
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Mapping brain to behavioral deficits in PTSD  
 
The core hypothesis driving our analytic approach is that clinically-meaningful 
biological heterogeneity within the broader clinical syndrome of PTSD can be 
understood by contrasting brain functional data (here with resting-state fMRI; Figure 2a) 
from patients with demonstrable information-processing i.e. cognitive impairments 
against functional data from healthy individuals and cognitively-intact patients with 
PTSD. We began by comparing performance on a battery of computerized 
neurocognitive tasks in healthy individuals and PTSD patients from Study 1 (see sample 
characteristics in tables S1 and S2). Given prior meta-analytic investigations of 
neurocognitive functioning in PTSD, we expected patients to show deficits in verbal 
learning and memory, attention, working memory, information processing speed and 
various executive functions (e.g. inhibition and flexibility)(7). To maximize the 
interpretability of our findings, we furthermore selected only unmedicated PTSD patients 
(N=36 healthy controls; N=56 patients). Looking at deficits in patients with respect to 
healthy individuals, only verbal memory delayed recall demonstrated a significant 
difference after controlling for a false discovery rate (FDR) of 0.05 (Wald c2=6.0, 
p=0.014, pFDR=0.0431; Figures 2b and S1). This small to medium effect size (Cliff’s 
delta=0.23) is consistent with that reported in a meta-analyses of neurocognition in 
PTSD(7). Since our goal was to identify a candidate cognitive phenotype for dissecting 
heterogeneity within PTSD, we created a cutoff in delayed recall scores using a 
discriminant function that determined the optimal value for differentiating patients from 
healthy individuals. Patients with delayed recall scores below this cutoff (90% accuracy 
or lower; 26% of PTSD cases, see supplemental results) were considered to be 
impaired relative to healthy individuals, while patients performing above this cutoff were 
considered to be cognitively intact. These groupings were then used for analysis of the 
neuroimaging data in both Study 1 and Study 2.  
We next examined whether functional connectivity abnormalities were observed 
selectively for the memory-impaired PTSD subgroup in resting-state fMRI analyses. 
Functional connectivity was calculated for each pair of cortical regions in a previously-
identified set of seven canonical cortical connectivity networks (37, 38)(Figure 2a). 
Pairwise connectivity values were then averaged based on region-network assignments 
to obtain one within-network connectivity value for each network and one between-
networks connectivity value for each pair of networks. These measures were then 
entered into a 3-level group factor generalized linear model (i.e. verbal memory 
impaired PTSD (N=12), verbal memory intact PTSD (N=39), healthy (N=36)), while 
controlling for age, gender, education and head motion. After FDR correction for all 
pairwise network-level connections, only connectivity within the ventral attention 
network (VAN) was found to differ among the three groups (Figure 2c; Wald c2=14.8, 
p=0.0006, pFDR=0.015). This network consists of parcels located in the insula, dorsal 
anterior cingulate, anterior middle frontal gyrus and supramarginal gyrus. A subsequent 
post-hoc pairwise contrast between the groups (using a Sidak correction for multiple 
comparisons) revealed that the impaired PTSD group had lower within-VAN connectivity 
relative to both healthy individuals (p=0.0001) and the intact PTSD group (p=0.03), 
while cognitive-intact patients with PTSD and healthy individuals did not differ. These 
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findings were not confounded by age, intelligence or performance on other cognitive 
tests (see supplemental results). 
We next tested whether the brain-behavior findings in PTSD patients found in 
Study 1 could generalize to a new cohort of patients and healthy controls. Study 1 used 
DSM-IV for diagnosis of PTSD and was composed primarily of civilians, was largely 
female, was all right-handed, featured patients who developed PTSD most commonly 
after physical or sexual assault, and used spiral in-out imaging. Moreover, only 
unmedicated patients were used in our primary analyses in Study 1. By contrast, Study 
2 used DSM-5 for diagnosis of PTSD and was composed entirely of Iraq/Afghanistan 
era military combat-exposed Veterans, was overwhelmingly male, included left-handed 
individuals, featured patients who developed PTSD almost exclusively after combat-
related events (N=117 healthy controls; N=128 PTSD participants), and used 
echoplanar imaging. Study 2 patients were also more frequently medicated 
(representing a broader variety of medications as well; see Tables S1 and S2). Thus, 
given predominant demographic differences, but similar neurocognitive and 
neuroimaging methodological approaches, the Study 2 sample represents a prime 
opportunity for testing the generalization of our brain-behavior findings from Study 1. 
The verbal memory impairment was also significantly more frequent amongst the PTSD 
group than healthy controls in Study 2 (33% of cases; Fisher’s exact test p=0.018; 
N=117 healthy controls; N=40 memory-impaired PTSD; N=83 memory-intact PTSD).  
We next examined the relationship of these a priori-derived verbal memory-
based groupings on within-VAN fMRI connectivity in Study 2. Using the generalized 
linear models and covariates defined in Study 1, while additionally controlling for 
acquisition site, the different medication classes represented in our population and 
handedness, we found a significant effect of verbal memory-based grouping on within-
VAN connectivity (Figure 3a; Wald c2=11.4, p=0.003). Specifically, within-VAN 
connectivity was significantly lower in verbal memory-impaired PTSD cases, relative to 
healthy individuals (p=0.042) and verbal memory-intact PTSD cases (p=0.002), after 
Sidak correction for multiple comparisons. Similarly, when considering all within- and 
between-network connections, the within-VAN connectivity effect also passed the FDR 
significance threshold (Figure 3b; pFDR=0.009). These results were likewise not 
confounded by age, intelligence or performance on other cognitive tasks (see 
supplemental results). 
 In summary, we found that a biobehavioral phenotype consisting of impaired 
delayed recall of verbal memory and blunted within-VAN resting state fMRI connectivity 
exists within the larger clinical syndrome of PTSD. This finding was observed in two 
independent cohorts, and was not related to potential confounding variables.  
 
Determining the clinical significance of impaired verbal memory and poor within-
VAN connectivity: current symptoms and comorbidities 
 
We next asked whether clinical aspects of PTSD, or its common comorbidities, 
differed in patients as a function of verbal memory delayed recall, within-VAN 
connectivity or their interaction. As detailed in supplemental results and Figure S2, we 
found no relationships of any of these variables, across either Study 1 or 2, to PTSD or 
depression severity (including PTSD symptom clusters and dissociative symptoms), 
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comorbid diagnoses, alcohol use, traumatic brain injury or quality of life. As such, it 
appears that, from a cross-sectional clinical perspective, the cognitive biobehavioral 
phenotype we have identified within the clinical syndrome of PTSD cannot be 
distinguished by current symptoms or comorbidities (i.e. clinically “latent”). We therefore 
next asked whether this phenotype was predictive of clinical outcome when PTSD 
patients are treated with the best-supported intervention for the disorder – exposure-
based psychotherapy.  
 
Determining the clinical significance of impaired verbal memory and poor within-
VAN connectivity: treatment outcome prediction 
 
Trauma-focused psychotherapy, such as prolonged exposure, is considered the 
gold-standard treatment for PTSD (superior to medications) and centrally involves 
therapeutic techniques that tap learning and memory (12, 39). Within Study 1, 66 
patients entered a randomized clinical trial contrasting prolonged exposure (PE; N=36) 
psychotherapy to a wait-list (WL; N=30) control arm, in order to understand the brain 
mechanisms underlying PE (Figure S3)(40, 41). As expected (39), PE resulted in a 
much greater reduction in PTSD symptoms, as assessed by the DSM-IV CAPS, than 
WL (F(2,113)=20.0, p= 4x10-8; Table S4), with no difference in dropout rates (Fisher’s 
exact test p=0.14).  
Using generalized linear mixed models in an intent-to-treat analysis, we next 
examined the potential moderating effects of verbal memory delayed recall and within-
VAN functional connectivity (i.e. whether these factors differentially predicted outcome 
with PE versus WL, as tested by a moderator by group by time interaction). When 
examined alone, neither verbal memory delayed recall impairment nor within-VAN 
functional connectivity significantly moderated treatment outcome (memory: 
F(2,90)=2.0, p=0.13; connectivity: F(2,108)=0.2, p=0.84). By contrast, when examined 
in interaction, there was a strongly significant moderation effect on treatment outcome 
as a function of both verbal memory impairment and within-VAN connectivity 
(F(2,82)=27.4, p<10-8; Figure 4a shows a median split on connectivity scores to 
illustrate the mixed model result). This model explained more treatment outcome 
variance than either single variable model alone (likelihood ratio test: ∆G2=102.8, df=6, 
p<0.001). Moreover, when considering all within- and between-network connections, the 
moderation effect for within-VAN connectivity is also significant after FDR correction for 
multiple comparisons (Figure 4b; pFDR=10-7). When testing each arm alone, we found 
that significant outcome prediction as a function of both memory and connectivity was 
found only in the PE arm (PE: F(1,41)=187.8, p<10-8; WL: F(1,41)=1.0, p=0.31). These 
effects were unrelated to any demographic variables, medication use or baseline PTSD 
severity, and had individual-level predictive value (see supplemental results). 
As seen in Figure 4a, the significant interaction in the PE arm arose from the 
poor treatment response of individuals with both impaired verbal memory and lower 
levels of within-VAN connectivity. Having either intact verbal memory or normal levels of 
within-VAN connectivity resulted in a robust treatment response. For context, a CAPS-IV 
cutoff of 20 is considered symptom remission (42), which many of the individuals 
without both the memory and connectivity impairments were able to achieve. Thus, the 
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biological stratification within the broader PTSD clinical syndrome discovered here is of 
clinical significance.  
 
 
 
Identifying the relationship of within-VAN fMRI connectivity to mechanisms of 
direct neurostimulation-evoked neural influence using spTMS/EEG  
 
Though resting-state fMRI connectivity is a broadly-used measure in both basic 
and clinical human neuroscience, which helped motivate our examination of this metric 
in this study, its physiological meaning remains unclear. That is, it is largely unknown 
how aspects of neurophysiology and directed information flow (as revealed by 
neurostimulation-evoked circuit perturbations) are reflected in individual differences in 
fMRI connectivity. By stimulating various cortical regions with concurrent spTMS/EEG 
one can discover the directional influence of the stimulated region on downstream 
regions (as contrasted with solely correlation-based connectomic mapping). We 
therefore next sought to understand neurophysiological mechanisms that may account 
for variations in within-VAN connectivity. For this goal, we conducted concurrent 
spTMS/EEG circuit interrogation by stimulating a TMS-accessible region of the VAN, 
located in the anterior middle frontal gyrus (aMFG(VAN); Figure 5a).  We contrasted 
results of VAN spTMS with stimulation of a nearby region in the posterior middle frontal 
gyrus located within the fronto-parietal control network (pMFG(FPCN); Figure 5a), also 
termed the executive control network. Importantly, in prior work using concurrent 
spTMS/fMRI, we found that spTMS to the right aMFG(VAN) node resulted in increased 
within-VAN fMRI connectivity relative to spTMS to the right pMFG(FPCN) node (43). 
Here we localized the VAN and FPCN nodes for neuronavigation in the same manner 
as our prior work, though now both left-sided and right-sided spTMS sites were 
included. These experiments were added to Study 2 after acquisition of fMRI and 
behavioral data had begun, thus a majority but not all participants underwent both fMRI 
and spTMS/EEG. 
As discussed in the introduction, EEG quantification of directed neural influence 
includes both phase-locked amplitude changes (TMS-evoked responses (TERs)) as 
well as changes in power of different frequency bands (event-related spectral 
perturbation (ERSP) changes). In order to cast a broad net across spTMS/EEG-
revealed neurophysiological mechanisms, we examined a broad range of TER 
measures (potentials at 30, 60, 100, and 200ms after the TMS pulse) and ERSP 
measures (across theta, alpha, beta and low gamma frequency ranges and in time bins 
extending up to 800ms after the TMS pulse; Figure 5b). These were extracted from a 
spatial mask covering VAN regions using an EEG source localization algorithm (44). We 
then correlated each individual’s within-VAN resting-state fMRI connectivity against 
each of the VAN-extracted TER and ERSP measures, correcting for multiple 
comparisons with FDR across the full set of correlations (i.e. each of four stimulation 
sites and all EEG measures). These analyses were done on participants in Study 2, a 
portion of whom additionally underwent spTMS/EEG (which was added after study 
recruitment had begun). As shown in Table S5, there were no demographic differences 
between those Study 2 patients who did and did not have spTMS/EEG data. 
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Furthermore, spTMS/EEG data were processed by an automated artifact rejection 
algorithm we recently developed (31), thereby minimizing the biases in preprocessing 
possible with manual rejection of artifacts, as is typically done in prior spTMS/EEG 
research. 
 After quality control of processed spTMS/EEG data (see methods) we had ~110 
participants with both spTMS/EEG and resting-state fMRI data across both healthy and 
PTSD groups (right aMFG(VAN) N=52 healthy/58 PTSD, left aMFG(VAN) N=50/63, right 
pMFG(FPCN) N=56/64, left pMFG(FPCN) N=50/48). Correlation analyses between 
fMRI connectivity and spTMS/EEG response were done across both healthy individuals 
and patients in order to identify generalizable neurostimulation-evoked neural influence 
signals in the spTMS/EEG data that may account for within-VAN fMRI connectivity, 
under the assumption that such a relationship is not specific to a distinct clinical 
diagnosis. We subsequently tested whether clinical group moderated these findings.  
 As seen in Figure 5c, multiple relationships between within-VAN fMRI 
connectivity and spTMS/EEG measures survived FDR correction, all of which were in 
response to stimulation of the right aMFG(VAN) node. All of these relationships were 
positive correlations and related to ERSP measures occurring largely after the phase-
locked TER ended. For example, as illustrated in Figure 5d, those individuals with lower 
within-VAN fMRI connectivity displayed profound VAN-localized alpha 
desynchronization (i.e. reduction in alpha power below baseline (defined as -300 to -
100ms)) in the 400-600ms post-spTMS pulse period, while those with higher fMRI 
connectivity showed either more modest or no desynchronization. To visualize these 
multiple fMRI-spTMS/EEG relationships, we show in Figure 5e ERSP plots for the 
individuals in the top third of the within-VAN fMRI connectivity distribution and those 
within the bottom third. As can be seen, there is profound and prolonged 
desynchronization in individuals with lower levels of within-VAN fMRI connectivity 
extending until the end of the 800ms time period across which we quantified ERSP 
measures. Put differently, while a neurophysiological response to a spTMS pulse ended 
by ~400ms for individuals with higher within-VAN connectivity, it persisted for at least 
800ms in those with lower within-VAN connectivity.  
 These fMRI connectivity-spTMS/EEG relationships were unchanged if we 
accounted for diagnostic group (healthy versus PTSD; Wald c2’s>8.4, p’s<0.004). 
Moreover, these findings were specific for the right aMFG(VAN) stimulation site. 
Covarying for the equivalent ERSP measure in response to right pMFG(FPCN) or left 
aMFG (VAN) stimulation did not eliminate the relationships between within-VAN fMRI 
connectivity and the various VAN ERSP responses to right aMFG(VAN) spTMS (Wald 
c2’s>6.4, p’s<0.012). In particular, the alpha desynchronization effect at 400-600ms 
post-spTMS pulse shown in Figure 5d survived both of these analyses at Wald 
c2’s>11.9, p’s<0.0006. 
In summary, using spTMS/EEG we discovered neural circuit influence signals 
that are associated with individual differences in resting-state within-VAN fMRI 
connectivity, and in a generalizable manner that was independent of clinical diagnosis. 
Specifically, we found that the lower the individual’s level of within-VAN fMRI 
connectivity, the more prolonged was their EEG responses to spTMS stimulation of a 
right-sided VAN region – responses that involved profound below-baseline 
desynchronization centered on alpha-range frequencies.  
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Discussion 
 
Here we have identified a biobehavioral phenotype within the broader clinical 
syndrome of PTSD, characterized by impairments in the delayed recall of verbal 
memory and resting-state fMRI connectivity of the VAN. This phenotype generalized 
across two independent and demographically/clinically distinct populations of patients 
and healthy individuals. It also powerfully moderated treatment outcome, despite being 
unrelated to current symptoms or comorbidities (hence clinically “latent”). Moreover, 
using concurrent spTMS/EEG to interrogate direct neurostimulation-evoked neural 
signal flow, we identified a neurophysiological circuit response that is associated with 
the degree of within-VAN fMRI connectivity. Specifically, we found that poorer within-
VAN connectivity was reflected in a more prolonged circuit perturbation to single TMS 
pulses delivered to a right-sided anterior prefrontal VAN region, taking the form of 
profound alpha-range below-baseline desynchronization. From a clinical perspective, 
these findings help ground clinically-meaningful variation within the syndrome of PTSD 
in objective and quantifiable features. From a translational perspective, by identifying 
neurophysiological direct stimulation-evoked signal flow correlates for altered within-
VAN fMRI connectivity we advance a basic understanding of on aspect of what, at least 
within-VAN, resting fMRI connectivity may index. Doing so thus also identifies a 
potential neurophysiological target for remediation through plasticity induction using 
repetitive TMS-based treatment targeting this region. 
 
Network and behavioral mechanisms of PTSD 
 
 Prior neuroimaging and behavioral work has generally treated PTSD as a single 
clinical group, contrasting PTSD cases with healthy participants (though DSM-5 now 
recognizes a dissociative subtype)(45). This has resulted in substantial inconsistencies 
in the literature. In the case of the VAN, for example, various authors have argued for 
over-activity or over-connectivity of the VAN in PTSD, by virtue of its response to salient 
stimuli such as threat cues (46, 47). However, results regarding resting-state VAN 
connectivity have been inconsistent, with evidence of both increased (48) and 
decreased (23, 49, 50) within-VAN connectivity. It has also been noted that 
abnormalities associated with PTSD are typically greater when comparing patients to 
trauma-naïve healthy controls but diminished, or even absent, when comparing to well-
matched trauma-exposed healthy controls (51, 52). Moreover, we are unaware of any 
prior report that applies the same analytical methods across two independent cohorts to 
determine whether a specific network connectivity finding generalizes across PTSD 
studies. 
Our findings argue that these inconsistencies and lack of generalization across 
cohorts or studies may stem from failure to account for the biological heterogeneity 
within the syndrome of PTSD, as well as an uncontrolled differential sampling of the 
heterogeneity that occurs in each study. Rather, consistent mechanistically- and 
clinically-meaningful neurobiological phenotypes in PTSD cases can emerge by 
anchoring stratification of PTSD clinical populations on objectively quantifiable factors, 
e.g. verbal memory and within-VAN functional connectivity. Moreover, while 
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neurocognitive impairments have been frequently found in PTSD (7), with verbal 
memory representing one of the areas of greatest impairment, many PTSD patients 
nonetheless perform within the healthy range. Hence, we focused our analyses on a 
differentiation of PTSD cases who were impaired on verbal memory (defined as 
performing outside of a discriminant-determined healthy range), compared to those 
PTSD cases who performed similarly to controls, and would thus be expected to look 
similar to controls in terms of relevant fMRI connectivity patterns. It is also important to 
note that were we to solely use subjectively reported or clinician-rated symptoms to 
identify this biobehavioral phenotype, we would have failed, as it was not consistently 
associated with differences in symptom expression, even though it powerfully predicted 
subsequent treatment response. Thus, our findings are consistent with recent proposals 
to shift away from symptoms for defining disorders to a brain information processing-
based approach (53).  
Consistent with our findings, a role of the VAN in verbal memory is suggested by 
multiple prior findings. Neuroimaging meta-analysis of activation during performance of 
memory tasks has found that activity in the VAN is associated with increased familiarity 
of remembered items (16), as well as in memory of verbal over pictorial stimuli (54). 
Resting-state fMRI within-VAN connectivity has also been found to predict delayed 
recognition memory (55). Memory impairments observed as part of “cognitive aging” 
have also been associated with decreased within-VAN connectivity (56, 57), though 
other findings have also implicated aberrant connectivity across a broader set of brain 
networks in memory impairment (17).  
We also note that while we found that verbal memory-impaired PTSD patients 
had lower within-VAN fMRI connectivity than both trauma-exposed controls and verbal 
memory-intact PTSD patients, impairments in memory and aberrant within-VAN 
connectivity are likely two	related but independent measures of what is likely a core 
deficit in an underlying information processing capacity, and are thus not redundant. 
Indeed, an interaction between these two factors was critical for effectively predicting 
treatment outcome. While most individuals with poor delayed recall of verbal memory in 
Study 1 also showed reduced within-VAN fMRI connectivity and poor treatment 
outcome, there are some memory-impaired individuals with healthy-range within-VAN 
fMRI connectivity that display favorable treatment outcomes. There may therefore 
appear to be an inconsistency between our association of memory impairments with 
poor within-VAN connectivity and the necessity of utilizing both measures to predict 
treatment outcome (rather than just one, were they to contribute entirely redundant 
information). However, poor delayed recall of verbal memory may occur due to multiple 
reasons, not all of which are related to the within-VAN memory processes implicated 
here per se (e.g. distractibility, attention, fatigue etc). These other reasons may index 
unrelated circuitry characteristics. As memory tasks require the interaction of multiple 
cognitive networks(16), within-VAN connectivity may be impaired in some individuals but 
memory performance may remain intact. Likewise, factors related to variations in 
individual mental processes indexed during resting state, as well as simple 
measurement error, may result in lower within-VAN connectivity for reasons not related 
to their relationship to verbal memory. In other words, each measure contains statistical 
“noise” relating to multiple factors that do not index the core neurocircuitry deficit 
characterizing subtype treatment resistance. In this way, the treatment prediction 
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findings are, in fact, the most telling. Specifically, only in those individuals who have 
both poor memory and low within-VAN connectivity (i.e. in whom there is confluence of 
measures mapping the core deficit) is treatment ineffective, and not so for individuals in 
whom these measures may diverge in indexing the core deficit due to noise or variance 
from other factors. 
Future work can build on these findings in several ways. We examined resting-
state connectivity, but different relationships may emerge when looking at memory task-
related fMRI connectivity. It may also be that a free recall-based verbal memory test 
may prove more sensitive to within-VAN connectivity abnormalities in PTSD as it suffers 
from less of an accuracy ceiling effect than the recognition-based recall task used in 
here. Moreover, given the role of the VAN in a range of cognitive operations (58, 59), 
other tasks that tap into these elements of VAN function may similarly be able to capture 
the phenotype we report here. It is also important to consider that every metric has its 
own test-retest-reliability, and even though verbal memory recall and fMRI connectivity 
both have relatively high levels of reliability, their covariation and treatment outcome 
prediction capacity is nonetheless gated by the reliability of each, as well as that of the 
outcome measure. Additional work is therefore necessary in refining which aspect(s) of 
verbal memory (or related constructs) and within-VAN resting fMRI connectivity are 
closely tied to one another in order to better understand this brain-behavior relationship. 
Finally, it will be important to test in future research whether both the relationship 
between within-VAN connectivity and verbal memory, and their joint relationship to 
treatment outcome, is specific to PTSD. As noted above, prior work has found 
associations between VAN functioning and memory unrelated to PTSD (55-57). There 
have also been implications of verbal memory alone in predicting outcome in disorders 
as diverse as bipolar disorder, psychosis and drug addiction(60-63), and we have found 
that disruptions in VAN are a feature common to many major psychiatric disorders (64, 
65). Thus, we cautiously speculate that the VAN/memory relationship will generalize to 
other conditions and predict poor treatment outcome in other contexts.  
 
Neurophysiological mechanisms of differences in within-VAN fMRI connectivity 
and implications for treatment 
 
 In this study, we sought to go beyond a correlative characterization of the 
biobehavioral phenotype discussed above, and identify potential neurophysiological 
mechanisms that may account for differences in within-VAN fMRI connectivity. To do 
this, we interrogated the concurrent EEG responses to single TMS pulse stimulation of 
bilateral VAN regions located in the anterior middle frontal gyrus, compared to a nearby 
posterior middle frontal region that is part of the FPCN. In prior concurrent spTMS/fMRI 
work, we found that stimulation of the same right VAN region, but not the right FPCN 
region, resulted in increased TMS-evoked within-VAN fMRI connectivity (43).  
We now found that lower levels of within-VAN fMRI connectivity were associated 
with profound below-baseline alpha-range desynchronization for hundreds of 
milliseconds (~400-800ms) after the TMS pulse. This result is important for multiple 
reasons. First, since no prior work has investigated the association of response to 
spTMS/EEG with resting fMRI connectivity, these findings open a new window into 
understanding the neurophysiological meaning of differences in fMRI resting 
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connectivity. Second, we found this relationship after rigorous correction for multiple 
comparisons and in a generalizable manner that was independent of clinical state. As 
such, we anticipate that these findings will be of broad relevance to fMRI research. 
More generally, our spTMS/EEG results also provide a perspective on which elements 
of causal signal flow within a network may relate to within-VAN fMRI-measured network 
connectivity, and establish spTMS/EEG as a brain mapping tool for understanding the 
neural basis of resting state fMRI network measures when applied across other 
networks and stimulation sites. 
One way to contextualize our findings is that normal levels of within-VAN resting-
state fMRI connectivity (e.g. as typical of memory-intact patients or healthy controls) 
may make the VAN resilient to perturbation by a TMS pulse. In those individuals, the 
phase-locked response (i.e. TER) and oscillatory power changes (i.e. ERSP) largely 
return to baseline by ~400ms. By contrast, the same network may be more susceptible 
to perturbation by the TMS pulse in individuals with lower within-VAN connectivity (e.g. 
as typical of memory-impaired patients), wherein the oscillatory power changes 
continue for at least 800ms, which was the end of the EEG epoch we analyzed. Though 
presently unknown, it these results may carry implications for the effects that repeated 
TMS pulses, such as used in therapeutic repetitive TMS protocols, have on network 
neurophysiology across individuals with different levels of within-VAN fMRI connectivity. 
Individuals with low fMRI connectivity may, for example, demonstrate greater impact of 
the prior pulse on the next pulse by virtue of the prolonged period of alpha-range 
desynchronization from one pulse interacting with the next one. 
Though still little is understood about the specific mechanisms associated with 
this late alpha-range desynchronization, it has been reported in motor cortex stimulation 
that it reflects a non-phase-locked aspect of the spTMS/EEG response and that it is 
sensitive to agonists of either the gamma-aminobutyric acid (GABA)-A or GABA-B 
receptors (36). In both cases, alpha desynchronization is increased by drugs that 
stimulate those receptors, suggesting that the increased and prolonged alpha-range 
desynchronization observed in individuals with lower within-VAN connectivity may index 
a larger inhibitory response to VAN spTMS stimulation. This interpretation contrasts with 
a common view of alpha-range oscillatory power in task and resting-state contexts, 
which argues that alpha reflects local inhibitory processing (66), and thus greater alpha 
desynchronization might actually mean less inhibition. However, the relationship 
between task and resting alpha oscillations and spTMS-induced late alpha 
desynchronization remains to be investigated. Likewise, future work should examine the 
relationship between VAN alpha power at rest and spTMS-induced late alpha 
desynchronization since altered alpha power has been observed in PTSD (67), and pre-
spTMS alpha power has been found to predict aspects of the response to the spTMS 
pulse (68). 
Identification of the right anterior middle frontal VAN node as a brain target at 
which stimulation evokes within-VAN fMRI connectivity-correlated EEG responses also 
carries potential clinical implications. Specifically, it suggests that this region may be a 
promising target for remediating the within-VAN fMRI connectivity deficit found in 
memory-impaired PTSD patients. This possibility is further supported not only by our 
prior spTMS/fMRI work (43), but also by a recent finding that examined the impact of 
high frequency repetitive TMS stimulation of either the right or left-sided anterior middle 
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frontal gyrus VAN regions (69). In that study, repetitive stimulation at 10Hz, which is 
thought to increase neuronal excitability (34), resulted in increased within-VAN resting-
state fMRI connectivity, but only after stimulation of the right-sided VAN target. Though 
we do not know why the correlation with fMRI connectivity was lateralized to the right-
sided VAN spTMS/EEG target in our study, our findings are nonetheless consistent with 
those of the 10Hz repetitive TMS study (including with respect to lateralization). 
Intriguingly, the vast majority of repetitive TMS treatment studies for PTSD have 
targeted a right-sided prefrontal region in the vicinity of our VAN region (70-73) and 
have found clinical efficacy. Likewise, disruptive and facilitating TMS manipulations of 
nearby right-sided prefrontal regions have been found to alter memory encoding or 
recall (74, 75). Most exciting is the potential that optimizing the TMS treatment for the 
patient could be guided by monitoring changes in spTMS/EEG responses to right 
anterior middle frontal VAN node stimulation, including as a function of baseline within-
VAN connectivity.  
 
Limitations 
 
It is important to consider that while we identified consistent patterns of biological 
heterogeneity across two independent and clinically/demographically diverse samples, 
the treatment prediction findings need to be replicated and further developed for our 
treatment prediction finding to impact clinical care. Likewise, fMRI may be less well 
suited to ultimate clinical translation than EEG.  
 
Conclusion 
 
The shift from overly-broad symptom-based descriptive diagnostic approaches in 
psychiatry to mapping objectively-defined phenotypes and perturbing circuits for 
inferential power, as encouraged by our findings, holds great promise for deepening our 
understanding of the factors dictating clinical heterogeneity and variability in treatment 
response, uncovering mechanisms of illness, and establishing avenues for novel and 
personalized treatments. Moreover, the fact that an objectively-discriminated group of 
patients do not respond to standard evidence-based treatment for PTSD underscores 
the need to apply such an approach for the purposes of improving clinical decision-
making and patient outcomes.   
 
  
 
Figure 1: Overview of the experimental design. 
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Figure 2: Impairment in verbal memory delayed recall is associated with poor 
within-ventral attention network (VAN) resting-state fMRI connectivity in PTSD 
(Study 1). (A) 3-D renderings of the seven previously-identified set of seven canonical 
cortical connectivity networks used for resting-state fMRI connectivity analyses (other 
abbreviations: SMN=somatomotor network, DAN=dorsal attention network, 
FPCN=frontoparietal network, DMN=default mode network). (B) Only blunted verbal 
learning delayed recall in PTSD cases survived FDR correction across the 
neurocognitive tests examined (Wald c2=6.0, p=0.014, pFDR=0.0431). # FDR p<.05. (C) 
Results of the 3-level effect of group (healthy, impaired memory PTSD patients, intact 
memory PTSD patients) in generalized linear models predicting each network to 
network connectivity pair. The plot show –log10(p-value) of the effect of group term. Only 
within-VAN connectivity survived FDR correction (Wald c2=14.8, p=0.0006, pFDR=0.015; 
white asterisk). (D) Bar graph showing the group effect on within-VAN connectivity, 
demonstrating impaired connectivity only in the impaired PTSD group, relative to both 
the healthy and intact PTSD groups. * p<.05, *** p<.001. Bar graphs show means and 
standard errors (for normally distributed variables), while box and whisker plots show 
medians, interquartile ranges, minima and maxima (for variables with skewed 
distributions). 
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Figure 3: Generalization of the memory-related within-VAN fMRI connectivity 
impairment to an independent sample of patients and controls (Study 2). (A) 
Results of the 3-level effect of group using the same cutoffs and analytical approach as 
in Study 1. This demonstrates replication of the reduction in within-VAN fMRI 
connectivity only in the impaired memory PTSD group, relative to both the healthy and 
intact memory PTSD group (Wald c2=11.4, p=0.003). (B) The memory-related 
impairment in within-VAN fMRI connectivity also survived FDR correction across all 
network pairs (pFDR=0.009). The plot show –log10(p-value) of the effect of group term. * 
p<.05, ** p<.01. Shown are means and standard errors. 
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Figure 4: Poor treatment outcome for patients with impairments in memory and 
within-VAN connectivity (Study 1). Patients were randomized to a highly evidence-
based psychotherapy treatment (prolonged exposure (PE)) or a wait list control (WL). 
(A) Generalized linear mixed models in an intent-to-treat analysis revealed a highly 
significant moderation effect (treatment group by memory by connectivity by time 
interaction). A median split on the fMRI connectivity variable is shown for illustrating the 
mixed model result (i.e. low/high connectivity). (B) Within-VAN connectivity likewise 
survived FDR correction across all network pairs in moderating treatment outcome 
(pFDR=10-7; white asterisk) based on the treatment group by memory by connectivity by 
time interactions term. The plot show –log10(p-value) of this term for each network pair.  
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Figure 5: Relationship of within-VAN resting-state fMRI connectivity to 
neurophysiological causal circuit influence signals detected using concurrent 
spTMS/EEG. (A) TMS was delivered to one of two stimulation sites, bilaterally. These 
sites were identified based on independent components analyses on resting-state fMRI 
data from a separate cohort (yellow clusters). The TMS targets (white spheres) were 
either in the anterior middle frontal gyrus (aMFG, part of the VAN) or posterior middle 
frontal gyrus (pMFG, part of the FPCN). (B) Illustration of the spTMS/EEG signals 
quantified, which covered both TMS-evoked responses (TERs) and event-related 
spectral perturbations (ERSPs). See online methods for the TER time windows and 
ERSP frequency ranges. Dashed line indicates the timing of the TMS pulse. (C) A 
significance plot of the generalized linear models relating individual differences in within-
VAN fMRI connectivity across all participants (healthy and PTSD) to individual 
differences in each EEG measure, for each of the stimulation sites. All EEG measures 
reflect an average of the denoted source-space signals across all vertices comprising 
the VAN, thus correlating within-VAN fMRI connectivity to the various EEG responses in 
the VAN to stimulation of various cortical sites. Only ERSP measures for right 
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aMFG(VAN) stimulation survived FDR correction (denoted by asterisks). The plot show 
–log10(p) of the correlation of within-VAN fMRI connectivity with spTMS/EEG measures.  
(D) Scatter plot of one of the FDR-significant relationships, demonstrating that 
individuals with lower within-VAN fMRI connectivity had a more profound alpha-range 
desynchronization 400-600ms after the TMS pulse (i.e. below-baseline levels of alpha 
power). (E) ERSP plots for illustration of the significant findings. We averaged the 
ERSPs for participants in the top and bottom third of the within-VAN fMRI connectivity 
distribution in order to be able to visualize the correlation findings across the whole 
time-frequency range. This demonstrates the prolonged and profound alpha-range 
desynchronization from ~400 to ~800ms after the TMS pulse associated with reduced 
levels of within-VAN fMRI connectivity.  
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Materials and Methods 
 
Methods are presented here in brief, with full details available in the supplemental 
materials. 
 
Study Design 
 
We report on data from two studies, including cross-sectional case-control data 
from both studies (involving healthy participants and those with PTSD), as well as 
longitudinal treatment outcome data from Study 1. Each study includes fMRI, 
behavioral, clinical and demographic measures, while Study 2 additionally includes 
spTMS/EEG data. The primary analyses are cross-sectional and focus on relating 
variation in cognitive task performance among PTSD patients (and with respect to 
healthy individuals) to variation in resting-state network connectivity. Additional cross-
sectional analyses test how these brain-behavior relationships correlate with clinical 
symptoms, as well as the degree to which they can predict treatment outcome in a 
longitudinal analysis. Finally, we relate fMRI connectivity to spTMS/EEG-investigated 
directional neural signal flow in a subsequent cross-sectional analysis. 
 
Participants and procedures 
 
Figure 1 shows an overview of the experimental design. Study 1 included 112 
primarily civilian participants (36 trauma-exposed healthy controls and 76 patients with 
PTSD), who underwent clinical, fMRI and behavioral assessments. Of these patients, 
66 went on to a randomized controlled trial comparing prolonged exposure (PE) 
psychotherapy treatment to wait list. The PE protocol followed well-described 
procedures and was supervised by a leading expert in PE (B.O.R.). Study 2 included 
245 Iraq/Afghanistan era combat veterans, with 117 being trauma-exposed healthy 
veterans and 128 having PTSD. They underwent the same assessments as Study 1 
participants, as well as concurrent single pulse TMS/EEG probing of neural excitability 
to direct non-invasive stimulation. Study 2 participants did not get treatment.  
 The behavioral assessments were conducted through a computerized 
neurocognitive battery that probed verbal memory, attention, working memory and 
response inhibition. The fMRI consisted of an 8-minute resting-state fMRI scan, 
conducted either using spiral in-out imaging at Stanford (Study 1) or as a two-site study 
using echoplanar imaging at Stanford and New York University (Study 2). Stanford used 
a General Electric 750 3T Scanner, while New York University used a Siemens Skyra 3T 
scanner. Preprocessing and connectivity assessment followed conventional procedures. 
 The TMS/EEG assessment involved stimulation with single TMS pulses to 
several sites within the prefrontal cortex, localized to either the VAN or FPCN, while 
measuring concurrent EEG responses. Preprocessing was accomplished through an 
automated artifact rejection algorithm previously published by our group, and EEG 
source localization followed conventional procedures.   
 
Statistical Analyses 
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 All statistical analyses were conducted in SPSS software (IBM Corporation, New 
York) and primarily used generalized linear models, with the principle exception of the 
treatment outcome prediction analyses, which used generalized linear mixed models. All 
tests and post-hoc analyses were corrected for multiple comparisons, the details of 
which are described in the appropriate sections of the main text, using two-sided tests. 
A memory-based division of PTSD patients was established based on the cutoff in a 
discriminant analysis that compared performance of the healthy and PTSD groups on 
the verbal memory test. The same cutoff was used for all analyses in both Studies 1 and 
2. Analysis of treatment outcome prediction in the randomized clinical trial followed an 
intent-to-treat framework that incorporated all randomized study participants in the 
analysis.  
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SUPPLEMENTAL MATERIALS 
 
Methods 
 
Participants 
Study 1 
Study 1 included 112 right-handed subjects in the primary component of 
this study, including 76 patients with PTSD, and 36 trauma-exposed healthy 
subjects (demographics and clinical characteristics in Supplemental Tables 1-4). 
All participants were recruited and scanned at Stanford University after signing a 
Stanford institutional review board-approved informed consent form, in 
accordance with the ethical principles in the Declaration of Helsinki. Out of the 76 
PTSD patients, 59 were unmedicated and thus were the focus of the primary 
analyses of cognition and fMRI connectivity. Furthermore, 66 of the 76 patients 
participated in a randomized clinical trial comparing prolonged exposure therapy 
to a wait-list control (clinicaltrials.gov identifier NCT01507948). Of these 66 
patients, 51 were unmedicated and included amongst the 59 patients noted 
above, while 15 were on stable doses of an antidepressant (demographic and 
clinical characteristics in Supplemental Table 5). 
Psychiatric diagnoses, or absence thereof for controls, were based on 
DSM-IV criteria using the Clinician-Administered PTSD Scale (CAPS) (76) for 
PTSD and the Structured Clinical Interview for the Diagnostic and Statistical 
Manual of Mental Disorders Axis I (SCID I) for other Axis I disorders (77). 
Participants were permitted to meet diagnostic criteria for comorbid mood and 
anxiety disorders secondary to PTSD. General exclusion criteria for both groups 
included the following: a history of psychotic, bipolar or substance dependence 
(within 3 months for patients and lifetime for controls), a history of a neurological 
disorder, greater than mild traumatic brain injury (i.e. >30 minutes loss of 
consciousness or >24 hour post-trauma amnesia), claustrophobia, and regular 
use of benzodiazepines, opiates, thyroid medications, or other CNS medication. 
Trauma-exposed healthy controls were required to have experienced a criterion A 
trauma, but not meet lifetime criteria for any Axis 1 psychiatric disorder, including 
PTSD.  
 
Study 2 
 Study 2 involved 245 participants, including 128 with PTSD, and 117 
trauma-exposed healthy participants (see Supplemental Tables 1-3). All 
participants were combat veterans serving during the Operation Iraqi Freedom 
(Iraq), Operation Enduring Freedom (Afghanistan) and Operation New Dawn 
periods. Participants were recruited and scanned at either Stanford University or 
New York University after signing an informed consent approved by the relevant 
University’s institutional review board, in accordance with the ethical principles in 
the Declaration of Helsinki. Similar inclusion/exclusion and diagnostic criteria 
were used as above except that diagnoses were based on DSM-5(2) criteria 
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rather than DSM-IV(1). Participants were allowed to continue their current 
medications as long as the dose was stable for two months. 29% of the PTSD 
patients were taking a psychiatric medication (see Supplemental Table 1).  
 
Treatment protocol (Study 1) 
Treatment randomization and study flow 
Following completion of baseline clinical assessments and fMRI scan, 
participants were randomized to one of two arms – treatment with prolonged 
exposure therapy, or a treatment waitlist – based on whether a number 
generated for each participant by a random number generator was odd or even. 
A total of 66 individuals were randomized 1:1 by study staff after completion of 
baseline clinical and neuroimaging assessments, with 36 being randomized to 
immediate treatment, and 30 to treatment waitlist (see CONSORT diagram, 
Figure S3; clinicaltrials.gov registration #NCT01507948). The duration of the 
clinical trial was from December 2010 through June 2015. The sample size was 
determined based on a priori power calculations to achieve significant 
differentiation in clinical outcome between exposure therapy and waitlist. Given 
the nature of the intervention and design, blinding of patients is not possible. If 
randomized to prolonged exposure, participants commenced treatment with a 
clinical psychologist trained to deliver prolonged exposure therapy.  If 
randomized to treatment waitlist, individuals were instructed they would have a 
10-week waiting period after which they would undergo a second clinical 
assessment and fMRI scanning session.  After completion of this second 
assessment, individuals on treatment waitlist were then assigned to a study 
therapist for completion of prolonged exposure therapy (to ensure all participants 
received study treatment). However, treatment after wait-list was outside of the 
intent-to-treat randomization framework, and thus not analyzed here. There were 
no adverse events reported in the course of the study. 
 
Treatment Frequency and Length 
Treatment sessions occurred on either a once or twice-weekly basis, for a 
total of either 9 or 12 90-minute sessions.  At sessions 2, 4, 6, and 8 individuals 
were administered the PTSD-Checklist Civilian Version for DSM-IV (78) as well 
as the Beck Depression Inventory-II (79) to track response to treatment.  The 
benchmark used to establish adequacy of treatment response at Session 9 and 
subsequent termination was at least a 70% reduction in Session 8 PCL-C scores 
from the PCL-C total score at intake.  If individuals met this benchmark, they 
were given the option to discontinue treatment after Session 9.  If individuals did 
not meet this benchmark and/or wished to continue for an additional 3 sessions, 
treatment was terminated after Session 12.  If treatment continued to 12 
sessions, PCL and BDI measures were also administered at Sessions 10 and 12.  
 
Therapist Competency and Supervision in Prolonged Exposure 
All psychologists received training in delivery of prolonged exposure and 
were deemed to meet competence in delivery of the treatment by one of the 
treatment developers, consultant to the study, and clinician supervisor Barbara 
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Rothbaum, Ph.D.  Dr. Rothbaum provided weekly group supervision to study 
therapists and reviewed video recordings of treatment sessions to rate 
compliance with the treatment protocol.  Dr. Rothbaum watched the entirety of 
the first three treatment sessions for each therapist to ensure therapist familiarity 
and competence with all major components of the treatment (all delivered in the 
first three sessions), and she continued to review relevant portions of remaining 
sessions as directed by study therapists.  All study therapists demonstrated good 
compliance with the therapy protocol and with no significant deviations, as 
demonstrated by good-to-excellent supervisor ratings of treatment session 
adherence. 
 
Treatment Structure 
Prolonged exposure therapy was delivered according to manualized 
procedures(80).  All sessions were audio recorded on a digital voice recorder 
(entrusted to the patient to take home with them and for use in completing 
imaginal exposure homework assignments) as well as a digital video recorder 
(for the purposes of assessing treatment adherence, therapist competency, and 
clinical supervision).  In brief, the structure and progression of treatment is as 
follows.  Session 1 consisted of psychoeducation on posttraumatic stress 
disorder symptoms, the rationale for treatment, and treatment structure.  It also 
involved additional assessment by the therapist of trauma history (including the 
index trauma, already established at intake), current symptoms, and current 
impairment.  Breathing retraining was taught at the end of Session 1 and 
practiced collaboratively in session, which consisted of a normal inhalation and a 
controlled and slow exhalation with internal repetition of a calming word or 
phrase (e.g., “Calm”) and a pause between exhalation and next inhalation, which 
was audiotaped for the patient.   
Session 2 consisted of homework review, self-report measures, a 
discussion of common reactions to trauma, a rationale for exposure as a 
treatment tool, construction of an exposure hierarchy for in-vivo exposure 
exercises, and selection of 2 to 3 hierarchy items for homework practice.  
Session 3 involved homework review, a brief rationale for imaginal exposure, and 
the first imaginal exposure in session for 45-60 minutes.  This was followed by a 
processing portion in which the therapist and participant discussed the 
participant’s experience of the exposure, any insights received through that 
process, and areas to be further addressed in future exposures.  Homework was 
then assigned (including completion of in-vivo exposures and imaginal exposures 
daily, and practice of breathing retraining).  Session 4 consisted of the same 
format as Session 3.   
Beginning in Session 5, the concept of trauma memory “hotspots” was 
discussed with participants, which were points in the memory during which the 
participant expressed the highest level of distress.  The in-session imaginal 
exposure began to shift towards emphasizing hotspots in the memory in Session 
5, at earliest, and sometimes Session 6 if agreed to be clinically appropriate by 
the participant and therapist.  Session 6, 7, and 8 involved a similar format, with 
homework review, imaginal exposure to “hot spots”, processing, and homework 
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assignment.  For participants reaching the PCL clinical benchmark in Session 8, 
and agreeing to end in 9 sessions, Session 9 consisted of homework review, a 
brief imaginal exposure of the entire trauma memory conducted in-session (20-
30 minutes), a brief processing, and a final review of treatment progress and 
skills acquired.  For participants not reaching the clinical benchmark and/or 
wishing to continue for an additional 3 sessions, Sessions 9-11 maintained the 
same format as Sessions 4-8.  In this case, Session 12 served as the final 
session (which assumed the aforementioned format). 
 
Post-Treatment Clinical Assessment 
Approximately 4 weeks following the final treatment session, participants 
were invited to return to complete a post-treatment clinical assessment.  A 4-
week period was chosen to intercede between final session and post-treatment 
assessment in order to allow treatment changes to consolidate and symptom 
levels to equilibrate.  Participants were administered the CAPS and SCID again 
at post-treatment to assess change in PTSD symptoms and comorbid diagnoses.   
 
Clinical and behavioral assessments 
 
Questionnaires and clinical scales 
 In addition to quantification of PTSD symptoms using the CAPS (for DSM-
IV in Study 1 and DSM-5 in Study 2) and assessment of comorbid diagnoses 
using the SCID, participants across all studies also completed several self-report 
questionnaires. This included quality of life using the World Health Organization’s 
WHOQOL-BREF survey (81), and depression using the Beck Depression 
Inventory II (79). Intelligence quotient (IQ) was estimated in both studies using 
the Wechsler Abbreviated Scale of Intelligence (WASI)(82). TBI was diagnosed 
in Study 2 based on loss of consciousness(83). 
 
Neurocognitive test battery 
 
We administered the same standardized computer-based neurocognitive test 
battery (84, 85) to participants in both studies, and which we had previously used 
in research on depression (86). The following cognitive tasks (and domains) were 
assessed:  
 
Word list learning task (verbal memory): Participants are presented visually with 
20 English words per learning block, one at a time, which they are asked to 
memorize. Words are closely matched on concreteness, number of letters and 
frequency. Each block ended with a test of immediate recall, which was done by 
presenting 20 sets of 3 words, only one of which was previously presented 
(which participants are asked to indicate). Learning occurred and was tested over 
three repetitions of the word list learning and immediate recall test blocks, with 
word combinations altered across the retention tests for each block. A delayed 
recall test is done 15 minutes later with another 20 sets of 3 words. Behavioral 
analyses were conducted on accuracy. 
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Continuous performance task (sustained attention): Participants view a series of 
letters (D, C, G or T) and indicate when the current letter is the same as one 
letter prior (display time 200ms, ISI 2600ms). There are 63 stimuli in total, with 12 
trials in which the current letter is the same as the prior letter. Behavioral 
analyses were conducted on accuracy and correct trial reaction time. 
 
Digit span forward task (working memory): Participants are presented visually 
with series of digits of varying lengths, and asked to enter those digits in the 
order in which they were presented. The first trial includes 3 digits, and two trials 
are presented at the same length level, followed by a progressive increasing of 
the digit span length across trials. The task ends after 2 incorrect trials at the 
same length level, or when the maximum 9-digit length is reached. Behavioral 
analyses were conducted on the maximum recall span. 
 
Color-word Stroop interference task (inhibitory control): Participants complete two 
conditions, one in which they indicate they indicate the name of color words 
(ignoring font color), and another where they indicate the color that the word was 
presented in (ignoring the word). In each trial, there are one of four different color 
words (red, blue, yellow, green), displayed in one of four colors (red, blue, yellow, 
green), with four buttons displayed underneath for the participant’s response 
(one for each color word, all in black font). Stroop interference is calculated on 
correct trial reaction times by subtracting word naming from color naming. 
 
Go/NoGo task (response inhibition): Participants see the word ‘PRESS’ appear 
repeatedly on the screen (display time 500ms, ISI 500ms). Green presentations 
(126 trials) indicate that participants should press the space bar as quickly as 
they can, while for red presentations (42 trials) participants are to withhold their 
response. Behavioral analyses were conducted on accuracy and correct trial 
reaction times. 
 
Trails B task (flexibility): Participants are asked to connect a series of 13 digits (1 
to 13) and 12 letters (A to L) in alternating digit/letter sequence (1-A-2-B, etc) 
using their mouse. Correct responses are accompanied by a line appearing 
between the last and current choices. Behavioral analyses are conducted on 
accuracy and average connection times between letters/numbers. 
 
Choice reaction time task (processing speed): Participants indicate with arrow 
keys which of two black circles turned green on the screen. The green circle 
stays green until the correct response is made. There are 20 pseudo-randomly 
presented trials, with a 2-4 second jittered inter trial interval. Behavioral analyses 
are conducted on correct trial reaction times. 
 
MRI data acquisition and preprocessing 
 
General scan parameters.  
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All resting-state fMRI scans were eight minutes in length. Imaging for the 
participants in Study 1 was performed on a 3T General Electric 750 scanner at 
Stanford University. Participants in Study 2 were scanned either on the Stanford 
GE 750 scanner or at NYU on a Siemens 3T Skyra scanner.  
For Study 1, 29 axial slices (4-mm slice thickness) were acquired covering 
the whole brain, using a T2- weighted gradient-echo spiral-pulse sequence 
(repetition time, 2000 ms; echo time, 30 ms; flip angle, 80 degrees; slice spacing, 
0.5; field of view, 22cm; matrix size, 64x64) (87). An automated high-order 
shimming method based on spiral acquisitions was used before acquiring fMRI 
scans (88) in order to reduce blurring and signal loss arising from field 
inhomogeneities. In addition, for retrospective correction of physiological motion 
effects in fMRI, RETROICOR was used (89). A high-resolution T1-weighted 
structural scan was acquired as follows: three-dimensional inversion recovery 
spoiled gradient-recalled acquisition in the coronal place with the following 
parameters: inversion time = 300 ms, TR = 8 ms, TE = 3.6 ms, flip angle = 15°, 
field of view = 22 cm, 124 slices, matrix = 256x192, acquired resolution = 1.5 x 
0.9 x 1.1 mm. For Study 2, both sites acquired 32 axial slices with 3.5mm 
thickness using an echo-planar gradient-echo T2-weighted pulse sequence 
(repetition time, 2000ms; echo time, 29 ms; flip angle, 90 degrees; slice spacing, 
0; field of view, 20cm; matrix size, 64x64). A high-resolution T1-weighted 
structural scan was acquired as follows: three-dimensional MPRAGE in the 
sagittal place with the following parameters: inversion time = 450 ms, TR = 8.21 
ms, TE = 3.22 ms, flip angle = 15°, field of view = 24 cm, 184 slices, matrix = 
256x256, acquired resolution = 0.9375 x 0.9375 x 1.0 mm. For both Studies 1 
and 2, the quality of fMRI scans was monitored by MRI center staff weekly with 
scans of an Functional Biomedical Informatics Research Network (fBIRN) agar 
phantom, as previously described (90, 91).   
For Study 2, as it was a two-site MRI study, prior to study initiation, we 
harmonized image acquisition sequences across the two scanners. This involved 
both assessing image quality and signal to noise ratio (SNR) of images acquired 
using different parameters at each site, as well as acquisition of the same 
sequences on several traveling non-study control participants. Scanning of 
traveling non-study controls was repeated at roughly mid-study. Though the 
same acquisition sequences were used at both sites, differences between 
scanners are expected. For example, the echo-planar resting-state scans 
typically had more ventral prefrontal and temporal lobe susceptibility-artifact 
dropout at the Stanford site than the NYU site. The slice-based SNR was also 
significantly higher at NYU than at Stanford (mean (SD) for NYU: 235 (78) and 
Stanford: 194 (51); Wald c2=17.2, p= 0.00003). These differences in acquisition 
site were accounted for using a site variable in all statistical models for Study 2. 
During the progress of the study, assessment of signal quality and stability 
was done as follows. For each scan, quality was assessed by quantitative and 
qualitative factors, with results regularly reported to MRI center staff and principle 
investigators at weekly meetings.  Quantitative factors include: scan parameters 
(check for correctness), slice-based signal to noise ratio, and total root mean 
square head motion as well as framewise displacement. We also monitored 
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scanner performance by tracking reference voltage, imaging frequency, and bias 
field correction over time. Reference voltage (aka RF transmit reference voltage) 
determines the amplitude of the RF pulses. Imaging frequency variations can 
indicate scanner problems. The scanner’s central frequency is typically set to the 
resonance frequency of water photons.  Measurements of this are proportional to 
the field strength, and imaging frequency is a common calibration parameter and 
can be found in every image’s DICOM header. Variations that exceed reference 
values can indicate magnet drift or RF instability. Qualitative factors were 
assessed visually by a trained image quality assessor.  These included field of 
view clipping, wrapping, dropout, ringing/ striping, blurring, ghosting, RF 
problems (noise, spikes, leakage), and inhomogeneity.  
 
Preprocessing 
The first 5 acquired volumes (10 seconds) were dropped, the data were 
then motion corrected using FSL’s mcFLIRT 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/MCFLIRT). The non-linear registration to 
standard space was performed using FSL’s FNIRT, registration from functional to 
T1-weighted structural images was estimated using FSL’s implementation of 
boundary-based registration (fsl.fmrib.ox.ac.uk/fsl/fslwiki/FLIRT_BBR). The mean 
white matter (WM) and cerebral spinal fluid (CSF) signal was estimated from the 
time-series using an MNI space defined WM/CSF mask transformed to the native 
functional space. The functional time-series was residualized with respect to the 
estimated WM/CSF signal. The data were then spatially smoothed with full-width 
half-maximum (FWHM) Gaussian of 6mm, consistent with our prior work and 
how our connectivity atlas was previously used (92). The data were residualized 
with respect to six motion parameters (estimated from mcFLIRT) to further 
account for motion effects.  Next, volumes with framewise-displacement of >0.5 
mm were removed from the data to further reduce motion-related artifact. Lastly, 
a bandpass filter was applied to data using cut-off frequencies of 0.008Hz – 
0.1Hz. Only subjects with maximum root mean square motion <3mm were 
included in analyses. 
 
fMRI connectivity analyses 
A set of 100 regions of interest (ROIs) were defined based on a recently-
published cortical parcellation derived from applying a combination of local 
gradient analysis and global signal similarity on an independent resting-state 
fMRI cohort (37). ROIs were mapped to seven previously identified functional 
networks (see Figure 2a) based on the spatial overlap between each ROI and 
each network (38). Connectivity strength was estimated using Pearson’s 
correlation coefficient between the mean signals from each pair of a priori ROIs, 
which were then converted to z-scores using Fisher’s r-to-z transformation. To 
further reduce data dimensionality in a meaningful way, we next used these 
values to calculate for each network the average within-network connectivity 
value as well as a pairwise between-network connectivity value for each pair of 
networks. This resulted in a set of 28 connectivity strength values representing 
		8	
the within- and between-network resting-state connectivity profile for each 
subject.  
 
spTMS/EEG data acquisition and preprocessing 
 
Data acquisition 
Anatomical targets for spTMS stimulation were determined based on an 
independent components analysis (ICA) of resting fMRI data from a separate 
group of individuals (43). These targets were then transformed to individual 
subject native space using non-linear spatial normalization with FSL 
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki) and used for TMS targeting. The targets were 
placed on each participant’s T1-weighted anatomical MRI for neuronavigation 
using the Visor2 LT 3D neuronavigation system (ANT Neuro, Netherlands). Each 
of four target sites were stimulated with 60 pulses (biphasic TMS pulses, 120% of 
resting motor threshold), interleaved at a random interval of 3 ± 0.3 seconds 
using a MCF-B65 butterfly coil and a MagPro R30 TMS stimulator (MagVenture, 
Denmark). TMS sites included the FPCN and VAN nodes within the middle 
frontal gyrus bilaterally, as previously described (43), with targets identified for 
both the left and right hemispheres. For the stimulation, the TMS coil was placed 
tangentially to the scalp with the handle pointing backwards and laterally at an 
angle of 45° to the sagittal plane. Participants were instructed to relax and to 
fixate at a cross located on the opposing wall during each stimulation.  
64-channel EEG data were recorded using two 32-channel TMS-
compatible BrainAmp DC amplifiers and the Easy EEG cap with extra flat, freely 
rotatable electrodes designed specifically for TMS applications (BrainProducts 
GmbH, Germany). Electrode impedances were kept below 5 kOhms. EEG data 
were sampled at 5 kHz and an electrode attached to the tip of the nose was used 
as the reference. The electrodes were digitized relative to the scalp at the end of 
the spTMS-EEG session using the neuronavigation system. To avoid the artifact 
introduced by the coil recharge, the recharge time was delayed by 1500 ms. 
 
Preprocessing, source localization and signal extraction 
The spTMS/EEG data were cleaned and analyzed using custom MATLAB 
(Mathworks, Natick, MA) scripts. Specifically, a fully automated artifact rejection 
algorithm that we developed recently was employed to clean the spTMS/EEG 
data (31): 1) The initial 10 ms data segment following TMS pulses were 
discarded to remove the large stimulation-induced electric artifact. 2) The EEG 
data were downsampled to 1 kHz. 3) Big decay artifacts were automatically 
removed using ICA based on thresholding. 4) The 60 Hz AC line noise artifact 
was removed by a notch filter. 5) Non-physiological slow drifts in the EEG 
recordings were removed using a 0.01 Hz high-pass filter, and high-frequency 
noise was removed by using a 100 Hz low-pass filter. 6) The spectrally filtered 
EEG data was then re-referenced to the common average and epoched with 
respect to the TMS pulse (-500 ~ 1500 ms). 7) Bad trials were rejected by 
thresholding the magnitude of each trial. Bad channels were rejected based on 
the spatial correlations among channels. The rejected bad channels were then 
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interpolated from the EEG of adjacent channels. 8) Remaining artifacts were 
automatically removed using ICA. ICs related to the scalp muscle artifact, ocular 
artifact, ECG artifact, were rejected using a pattern classifier trained on expert-
labeled ICs from other TMS/EEG data sets.  
Source localization was performed using the Brainstorm toolbox (93). A 
three-layer boundary element model of the head was computed with the 
OpenMEEG plugin (94) based on FreeSurfer average brain template (95). A total 
of 3,003 rotating dipoles were generated on the cortical surface. The lead-field 
matrix was obtained by projecting the standard electrode positions onto the 
scalp. The current density of each dipole was then estimated by the minimum 
norm estimation approach (44) with depth weighting and regularization.  
The source-space TMS-evoked response (TER) is defined as the average 
of the 3-D current density across trials and represents the phase-locked 
response to TMS. The event-related spectral perturbation (ERSP) is defined as 
the average of the log-time-frequency power maps of the 3-D current density 
across trials, with baseline correction (95). ERSP is suited for examining the 
induced oscillations that are not phase-locked to TMS. For each subject and 
stimulation site, the vertex-wise TER was computed by taking the norm of the 
TERs of all three orientations at each vertex. The network TER was then 
obtained by averaging the vertex-wise TER across all the vertices within the 
network, and assessed for the following time windows by averaging within each: 
p30 (25-35ms), p60 (45-70ms), n100 (100-150ms), p200 (175-225ms). Similarly, 
for each subject and stimulation site, the vertex-wise ERSP was computed by 
averaging the ERSPs of all three orientations at each vertex. The network ERSP 
was then obtained by averaging the vertex-wise ERSP across all the vertices 
within the network, and assessed for the following frequency bands: θ (4-7Hz), α 
(8-12Hz), β (13-30Hz), γ (31-50Hz), and time windows: 10-100ms, 100-200ms, 
200-400ms, 400-600ms, 600-800ms. For each stimulation site, participants 
whose average TER is beyond the 4 standard deviations from the mean TER 
across all participants were excluded from the group analysis to ensure only high 
quality spTMS/EEG data were analyzed. 
 
Statistical analyses 
 
All statistical analyses were conducted in SPSS software (IBM 
Corporation, New York). Unless stated otherwise, cross-sectional effects of 
categorical or continuous variables were assessed using generalized linear 
models (GLM). For each test, the data met the assumptions of the test reported, 
with appropriate variances between groups for the test (with variances 
summarized as either error bars in plots or standard deviations in tables). Post-
hoc tests of significant effects were conducted using Sidak correction for multiple 
comparisons on a significant GLM result. Each of the GLMs included a core set 
of covariates. For Study 1, this included core covariates for age, gender, 
education and head motion (as all participants were right-handed and the primary 
analyses used only medication-free patients). For Study 2, the core covariates 
included age, gender, education, head motion, site, handedness, and each of the 
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medication classes noted in Supplemental Table 1. Additional covariates in 
follow-up analyses are noted in the text for each of the studies. Correction for 
multiple comparisons was done using the false discovery rate (FDR), with each 
instance of FDR correction noted in the main text.   
The memory-based grouping of PTSD patients (i.e. impaired vs intact) 
was done in SPSS for Study 1 by entering the delayed verbal memory recall 
accuracy scores for patients and healthy controls into a discriminant analysis in 
order to determine the optimal cut-point that discriminates the two groups. This 
revealed that 90% accuracy (or below) was optimal for identifying patients. We 
therefore binarized patients into an intact memory group (ie >90% accuracy, thus 
performing within the healthy range) and an impaired memory group (≤90% 
accuracy, thus performing outside the healthy range). The same cutoff was 
subsequently applied to Study 2 in order to maintain the same definition of the 
impaired and intact groups. Binarization was done so that the neural correlates of 
memory-related impairments in patients could be examined with respect to both 
unimpaired patients and healthy individuals.  
For the treatment moderation analyses in the Study 1 treatment sample, 
we conducted intent-to-treat analyses using generalized linear mixed models 
(GLMM) with a robust estimator, to control for potential violations of model 
assumptions, implemented with a random intercept and fixed slope. This allowed 
us to include all participants who were randomized to PE or WL in the study, 
without the biases that may come from the typical completer studies conducted in 
neuroimaging studies. This also allowed us to examine moderator interactions 
with treatment-related change in symptoms while controlling for baseline 
symptom levels. The main GLMMs included factors for arm (PE vs WL), time (pre 
vs post), as well as within-VAN fMRI connectivity and/or the binarized verbal 
memory impairment variable defined above.  The following effects were specified 
in the combined verbal memory/within-VAN connectivity moderation model in 
order to account for all lower-order interactions that might influence the higher-
order four-way interaction effect of interest:  time, group x time, verbal memory, 
fMRI connectivity, fMRI connectivity x verbal memory, time x verbal memory, 
time x fMRI connectivity, time x fMRI connectivity x verbal memory, group x time 
x verbal memory, group x time x fMRI connectivity, and group x time x verbal 
memory x fMRI connectivity.  The F statistic corresponding to this latter 4-way 
interaction was used to assess a conjoint moderation effect of verbal memory 
and network efficiency on differential symptom change by treatment group. 
GLMMs examining only the moderating effects of memory or fMRI connectivity 
excluded the terms that include the variable no longer in the model. As these 
single moderator models reflect effects within the two interacting moderator 
model, we compared the memory/fMRI connectivity model to the single variable 
models using likelihood ratio tests to determine if the two moderator model 
explained significantly more variance in PE-related treatment outcome. 
Treatment-related changes in symptoms, memory and fMRI connectivity also 
used the same GLMM (including a random intercept and fixed slope), but 
included only terms for group and group x time interactions. 
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Results 
 
Memory performance of the memory-defined groups in Studies 1 and 2 
 
In Study 1, the median recall accuracy of the verbal memory-impaired 
PTSD subgroup was 82.5% (mean: 75%), indicating a notable performance 
impairment relative to the memory-intact PTSD subgroup (median/mean of 
100%/98%) and the healthy group (median/mean 100%/97%). In Study 2, the 
median recall accuracy of the verbal memory-impaired PTSD subgroup was 85% 
(mean: 78%), indicating a notable performance decrement relative to the 
memory-intact PTSD subgroup (median/mean of 100%/98%) and the healthy 
group (median/mean 98%/96%). 
 
Mapping brain to behavioral deficits in PTSD: investigating effects of 
potential confounding factors  
 
Study 1 
 
Amongst the three, verbal memory-based groups in Study 1, we found 
that age differed significantly, such that the impaired PTSD group was 
significantly older than both the healthy and intact PTSD groups (supplemental 
table 3; Wald c2=7.4, p=0.025; post-hoc pairwise impaired vs. healthy p=0.01, 
impaired vs. intact p=0.01). In addition to including age as a covariate in the 
analysis above, we verified in two additional ways that age was not the driving 
factor for the within-VAN connectivity differences we observed. First, amongst 
PTSD patients, we found that age itself was not significantly related to within-
VAN connectivity (Wald c2=0.9, p=0.34). Second, we noted that the group 
differences in age were driven by the impaired PTSD group having several more 
individuals >55 years old (our study inclusion maximum age cutoff was 60). Thus, 
we tested the effect of excluding all participants >55 years old, and again found 
significantly lower within-VAN connectivity in the impaired PTSD group relative to 
each of the other groups using the same generalized linear model as above 
(Wald c2=10.2, p=0.006), but now observed no group differences in age (Wald 
c2=3.6, p=0.16). Finally, we tested whether the same brain-behavior relationship 
could be observed when including the medicated PTSD participants in Study 1, 
and again found that within-VAN connectivity was selectively lower in the verbal 
memory impaired PTSD patients compared to either healthy individuals or verbal 
memory intact PTSD patients (Wald c2=13.8, p=0.001). Similar results were 
obtained including only Study 1 patients who went on to take part in the 
randomized clinical trial described further below (Wald c2=14.8, p=0.0006).  
Robustness of the identified relationship between verbal memory and 
within-VAN connectivity was further examined by repeating the test while 
controlling for general intelligence, as well as other cognitive measures. The 
memory-based grouping results held while controlling for general intelligence, in 
addition to the covariates noted above (Wald c2=20.2, p=0.00004). Likewise, the 
results held even after controlling for performance on other cognitive tests that 
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showed trend-level group differences in Figure S1, such as sustained attention 
accuracy and reaction times (Wald c2=20.3, p=0.00004), information processing 
speed reaction times (Wald c2=13.5, p=0.001), and working memory digit spans 
(Wald c2=14, p=0.0009). Within-VAN functional connectivity amongst patients 
also did not correlate with scores on these cognitive tests (Wald c2<1.9, p>0.19). 
We also considered the possibility that connectivity differences within the VAN 
reflected more basic/focal aspects of the signal fluctuation in VAN regions. Thus, 
we quantified the coefficient of variation within VAN regions, but did not find a 
significant effect of memory-based grouping on this measure (Wald c2=2.9, 
p=0.23). 
 
Study 2 
 
Beyond these large differences in samples noted in the main text, Study 2 
PTSD patients were also significantly younger and had lower general intelligence 
than Study 1 PTSD patients (Wald c2’s>6.0, p’s<0.015), although healthy 
individuals did not differ on either measure across studies (Wald c2’s<1.4, 
p’s>0.23). Notably, demographic factors did not significantly differ between PTSD 
cases and healthy individuals in Study 2 nor did these differ in Study 2 when 
using the verbal memory-based grouping defined above (see Supplemental 
Tables 1 and 3). Critically, there were also no significant differences in age 
between the memory-based groups either (Wald c2=1.9, p=0.39). 
As in Study 1, similar results were found in Study 2 using our memory-
based grouping when controlling for general intelligence (Wald c2=10.1, 
p=0.006), sustained attention accuracy and reaction times (Wald c2=12.1, 
p=0.002), information processing speed reaction times (Wald c2=11.7, p=0.006), 
and working memory digit spans (Wald c2=10.9, p=0.004). As in Study 1, we also 
did not find a significant effect of the verbal memory-based grouping on VAN 
coefficient of variation (Wald c2=4.1, p=0.13). 
 
Determining the clinical significance of impaired verbal memory and poor 
within-VAN connectivity: current symptoms and comorbidities 
 
We next asked whether clinical aspects of PTSD, or its common 
comorbidities, differed in patients as a function of verbal memory delayed recall, 
within-VAN connectivity or their interaction. These analyses first focused on 
general symptom measures that had been assessed in both Studies 1 and 2. As 
seen in Supplemental Figures 3a and 3b, we found no effect of memory, within-
VAN connectivity or their interaction on overall PTSD severity, as assessed by 
the Clinician-Administered PTSD Scales (CAPS) for DSM-IV or DSM-5 in Studies 
1 or 2, respectively (Wald c2’s<1.7, p>0.19). Repeating these analyses for CAPS 
subscales (three for Study 1 and four for Study 2), or CAPS dissociation items, 
failed to yield any significant relationships to memory, within-VAN connectivity or 
their interaction. Likewise, there were no significant effects of memory, VAN 
connectivity or their interaction on depression symptom scores in Studies 1 or 2 
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(Wald c2’s<3.1, p>0.08). The frequency of comorbidity with major depression, 
assessed similarly in both studies, did not differ as a function of verbal memory, 
VAN connectivity or their interaction (Wald c2<2.9, p>0.09). In Study 2 we 
assessed additional psychiatric disorders, but similarly found no significant 
differences between groups in the frequency of generalized anxiety disorder, 
panic disorder, social anxiety disorder, or alcohol use disorder (Wald c2<1.9, 
p>0.72). Finally, Study 2 included individuals with traumatic brain injury (TBI), 
indexed as an episode of head trauma-induced loss of consciousness. The 
frequency of TBI was nonetheless also not related to memory, VAN connectivity 
or their interaction (Wald c2’s<1.4, p>0.24). Finally, we examined the influence of 
memory, VAN connectivity and their interaction of patients’ quality of life on the 
World Health Organization Quality of Life scale, which has subscales for physical 
health, psychological health, social relationships and environment. However, no 
significant effect was observed after correcting for multiple comparisons within 
each study. As such, it appears that, from a cross-sectional clinical perspective, 
the cognitive biobehavioral phenotype we have identified within the clinical 
syndrome of PTSD cannot be distinguished by current symptoms or 
comorbidities (i.e. clinically “latent”). We therefore next asked whether this 
phenotype was predictive of clinical outcome when PTSD patients are treated 
with the best-supported intervention for the disorder – exposure-based 
psychotherapy.  
 
Determining the clinical significance of impaired verbal memory and poor 
within-VAN connectivity: treatment outcome prediction 
 
The treatment moderation results presented in the main text were 
unchanged when either controlling for age or excluding participants >55 years old 
(F’s>20, p’s<10-7). The moderation effects were also similarly significant when 
additionally controlling for any baseline symptom differences by treatment arm 
(F(2,82)=27.4, p<10-8), or medication use and demographic variables 
(F(2,78)=27.1, p<10-8). There were also no differences in baseline PTSD 
symptoms, verbal memory impairment or within-VAN fMRI connectivity between 
the treatment arms (Wald c2’s<1.9, p>0.17). 
In spite of the treatment-moderating effects of verbal memory and within-
VAN connectivity, neither memory nor connectivity showed a significant change 
following PE compared to following WL (Figure S4a and S4b; group x time 
interactions for memory: F(2,91)=2.3, p=0.11; connectivity: F(2,111)=0.02, 
p=0.98). This is consistent with the expectation that individuals with the greatest 
impairments in both measures failed to respond to PE, while those without both 
impairments (who responded well to PE) were already within the healthy range 
on both measures. 
Next, to understand the individual-level predictive value of memory and 
connectivity, we tested these two variables as potential predictors of treatment 
outcome (quantified as a binary response variable corresponding to a 50% 
decrease in symptoms) using support vector machine (SVM) classification with 
leave-one-out cross-validation within the PE arm only. We found that treatment 
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response could be predicted at 85% accuracy with a linear SVM (sensitivity 80%, 
specificity 87%; p=0.009 using 5,000 permutation tests) and at 90% accuracy 
with a non-linear radial basis function SVM (sensitivity 80%, specificity 93%; 
p=0.01). SVM’s using only memory or only connectivity scores did not predict 
outcome (accuracies £65%, p’s>0.18). Individual data points for memory, 
connectivity and treatment outcome can be found in parallel coordinate plots in 
Figure S5. Notably, as classification of outcome requires an observed post-
treatment symptom score, these analyses are thus no longer within the intent-to-
treat framework, but are nonetheless informative as they speak to individual 
outcome prediction. 
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Figure S1: Neurocognitive task performance in PTSD. Group comparisons using 
generalized linear models with appropriate distribution and link functions. Only verbal 
learning delayed recall survived FDR correction (see Figure 2b). Other domains 
tested include sustained attention (continuous performance task), working memory 
(digit span), inhibitory control (color-word Stroop interference), response inhibition 
(Go/NoGo task), flexibility (trails B task) and processing speed (choice reaction time 
task). Bar graphs show means and standard errors (for normally distributed 
variables), while box and whisker plots show medians, interquartile ranges, minima 
and maxima (for variables with skewed distributions). 
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Figure S2: No relationship between the memory/connectivity-related 
phenotype and symptoms in PTSD patients (Studies 1 and 2). Several 
aspects of the clinical presentation of PTSD were tested for their relationship to 
memory impairment, within-VAN fMRI connectivity, or their interaction in the 
PTSD patients in Studies 1 (A) and 2 (B), but no significant effects were 
observed. Shown here are overall PTSD symptoms (on the Clinician 
Administered PTSD Symptoms scale (CAPS)), and depression symptoms (on 
the Beck Depression Inventory (BDI)). Y-axes on each plot show the value of the 
scale noted in the title of each plot, as either a scatterplot against within-VAN 
fMRI connectivity (z-scored residual after regressing out the covariates in the 
model) or split by memory-based grouping in patients.  
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Figure S3: CONSORT diagram for the Study 1 treatment component 
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Figure S4: No differential change in either within-VAN connectivity (A) or 
delayed recall of verbal memory (B) following treatment (i.e. PE versus WL). 
Bar graphs show means and standard errors (for normally distributed variables), 
while box and whisker plots show medians, interquartile ranges, minima and 
maxima (for variables with skewed distributions).  
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Figure S5: Individual data points for verbal memory delayed recall, within-VAN 
fMRI connectivity and percent change in CAPS total scores with treatment in 
PE arm completers in Study 1. It is important to note that this plot by necessity only 
reflects individuals who had each of the moderator variables (fMRI connectivity, 
memory) and a post-treatment clinical score from which to determine treatment 
response (here quantified as % symptom reduction). As such, it does not directly 
reflect the primary statistical testing conducted in the manuscript using linear mixed 
models in an intent-to-treat framework, and thus is used for illustration purposes only. 
In order to visualize each of these variables on a common axis, we scaled each of 
them to a 0-1 range (i.e. (individual value – minimum)/range). Each participant is 
represented by a different arbitrary color. 
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Table S1: Demographic and clinical characteristics of participants with means and 
(standard deviations) for Studies 1 and 2. 
 Study 1 Study 2 
  healthy (n=36) PTSD (n=76) Healthy (n=117) PTSD (n=128) 
Age (yr) 34.8 (11.8) 36.8 (10.6) 31.9 (7.4) 33.5 (7.4) 
Education (yr) 15.3 (2.4) 14.8 (2.5) 15.4 (2.1) 15.2 (2.2) 
Gender (% female) 50% 59% 10% 13% 
WASI intelligence quotient (IQ) 112.0 (13.7) 110.7 (10.3) 109.2 (11.8) 102.8 (11.1) 
Using medications (% yes) 0% 19% 5% (all PRN) 29% 
Handedness (% right handed) 100% 100% 89% 90% 
       self-report      
Beck Depression Inventory 1.5 (1.8) 23.5 (8.5) 4.1 (6.1) 19.0 (11.9) 
WHOQOL physical health 88.2 (11.1) 51.1 (19.6) 81.3 (13.2) 60.6 (16.7) 
WHOQOL psychological 
health 75.4 (11.4) 39.1 (14.8) 71.8 (16.0) 51.1 (19.2) 
WHOQOL social relationships 76.7 (19.7) 35.9 (23.3) 66.0 (21.3) 50.8 (24.0) 
WHOQOL environment 79.8 (14.7) 52.1 (20.8) 72.1 (16.1) 59.1 (16.3) 
DSM-IV clinician scales      
CAPS total 1.9 (2.8) 69.1 (15.3)    
CAPS re-experiencing .4 (1.0) 18.2 (6.2)    
CAPS avoidance .5 (1.2) 28.3 (8.4)    
CAPS hyperarousal 1.0 (1.7) 22.7 (5.6)    
DSM-5 clinician scales      
CAPS total   3.0 (4.1) 26.6 (10.8) 
CAPS re-experiencing   .5 (1.1) 6.3 (3.3) 
CAPS avoidance   .2 (.8) 3.4 (1.8) 
CAPS hyperarousal   .6 (1.4) 8.5 (5.3) 
CAPS negative cognitions   1.7 (2.3) 8.1 (3.5) 
      Medications or class     
CAPS dissociation 0 (0) 2.0 (2.9) 0.02 (0.2) 0.15 (0.7) 
Antidepressant (% yes) 0% 19% 0% 15% 
Benzodiazepine (% yes) 0% 0% 0% 6% 
Opiate (% yes) 0% 0% 3% 6% 
Thyroid (% yes) 0% 0% 0% 1% 
Gabapentin (% yes) 0% 0% 0% 3% 
Hypnotic (% yes) 0% 0% 2% 11% 
Prazosin (% yes) 0% 0% 0% 6% 
Mood stabilizer (% yes) 0% 0% 0% 3% 
Stimulant (% yes) 0% 0% 0% 2% 
Antipsychotic (% yes) 0% 0% 0% 2% 
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Table S2: Trauma type details for Studies 1 and 2 (percent of PTSD participants 
endorsing a category for their index trauma). 
 
   
Civilian/military trauma type (% of patients) Study 1 
Natural Disaster/Fire/Explosion 8.5 
Physical Assault 23.7 
Assault with Weapon 6.8 
Sexual Assault 33.9 
Combat/War Zone Exposure 10.2 
Injury/Illness/Suffering/Death 16.9 
  
Military trauma type (% of patients) Study 2 
Intentional Use of Force (Torture, Physical Assault) 5.5 
Accident (Vehicle – Rollover, Collision) 3.1 
Perceived Elevated Threat of Attack 10.2 
Small Arms Fire/Fire Fight 18.8 
Sexual Assault 3.1 
Witnessed a Killed in Action 1.6 
Wounded or Dead Bodies/Body Parts 9.4 
Explosion 47.7 
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Table S3: Demographic and clinical characteristics of participants by memory-based 
groupings.  
 Study 1: memory-based grouping  
(only unmedicated patients) 
  
Healthy 
(n=36) 
Impaired PTSD 
(n=12)  
Intact PTSD 
(n=39) 
Age (yr) 34.8 (11.8) 44.3 (12.2) 33.7 (8.7) 
Education (yr) 15.3 (2.4) 15.1 (2.5) 14.8 (2.6) 
Gender (% female) 50% 64% 62% 
WASI intelligence quotient (IQ) 112.0 (13.7) 107.4 (12.9) 111.4 (9.8) 
Using antidepressants (% yes) 0% 0% 0% 
           self-report    
Beck Depression Inventory 1.5 (1.8) 24.2 (10.2) 22.6 (8.1) 
WHOQOL physical health 88.2 (11.1) 46.2 (23.6) 54.9 (17.9) 
WHOQOL psychological health 75.4 (11.4) 41.9 (15.5) 39.1 (15.1) 
WHOQOL social relationships 76.7 (19.7) 36.0 (27.3) 36.1 (23.4) 
WHOQOL environment 79.8 (14.7) 52.0 (25.0) 51.0 (20.7) 
DSM-IV clinician scales    
CAPS total 1.9 (2.8) 67.7 (19.5) 67.2 (13.5) 
CAPS re-experiencing .4 (1.0) 17.6 (6.4) 17.8 (5.6) 
CAPS avoidance .5 (1.2) 28.3 (9.4) 27.4 (7.7) 
CAPS hyperarousal 1.0 (1.7) 21.8 (6.6) 22.0 (5.0) 
CAPS dissociation 0 (0) 1.5 (2.2) 2.1 (3.0) 
     Study 2: memory-based grouping 
  
Healthy 
(n=117) 
Impaired PTSD 
(n=40) 
Intact PTSD 
(n=83) 
Age (yr) 31.9 (7.4) 33.9 (5.7) 33.0 (8.0) 
Education (yr) 15.4 (2.1) 15.3 (2.4) 15.1 (2.1) 
Gender (% female) 10% 5% 16% 
WASI intelligence quotient (IQ) 109.2 (11.8) 103.1 (10.8) 102.7 (11.2) 
Using medications (% yes) 5% (all PRN) 35% 24% 
Handedness (% right handed) 89% 92% 89% 
            self-report    
Beck Depression Inventory 4.1 (6.1) 18.7 (11.7) 19.1 (12.1) 
WHOQOL physical health 81.3 (13.2) 59.5 (14.0) 61.2 (18.2) 
WHOQOL psychological health 71.8 (16.0) 50.8 (18.0) 51.4 (20.2) 
WHOQOL social relationships 66.0 (21.3) 53.5 (28.3) 49.4 (21.3) 
WHOQOL environment 72.1 (16.1) 55.7 (13.8) 60.7 (17.4) 
DSM-5 clinician scales    
CAPS total 3.0 (4.1) 27.3 (11.6) 26.2 (10.5) 
CAPS re-experiencing .5 (1.1) 6.9 (3.5) 6.1 (3.3) 
CAPS avoidance .2 (.8) 3.6 (1.9) 3.4 (1.8) 
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CAPS hyperarousal .6 (1.4) 8.5 (5.2) 8.4 (5.3) 
CAPS negative cognitions 1.7 (2.3) 8.4 (3.3) 8.4 (3.7) 
      Medications or class     
CAPS dissociation 0.02 (0.2) 0.34 (1.1) 0.05 (0.3) 
Antidepressant (% yes) 0% 20% 11% 
Benzodiazepine (% yes) 0% 5% 6% 
Opiate (% yes) 3% 5% 7% 
Thyroid (% yes) 0% 3% 0% 
Gabapentin (% yes) 0% 3% 4% 
Hypnotic (% yes) 2% 8% 12% 
Prazosin (% yes) 0% 3% 6% 
Mood stabilizer (% yes) 0% 8% 1% 
Stimulant (% yes) 0% 0% 2% 
Antipsychotic (% yes) 0% 5% 1% 
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Table S4: Demographic and clinical characteristics of participants with means and 
(standard deviations) for the intent-to-treat analysis of treatment outcome and its 
moderation by verbal memory impairment and within-VAN fMRI connectivity. There 
were no differences between the groups in any of the baseline characteristics listed 
below (puncorrected>0.05). 
 
 Study 1 treatment sample 
  prolonged exposure (N=36) wait list (N=30) 
Age (yr) 34.4 (10.2) 39.0 (10.4) 
Education (yr) 14.7 (2.2) 15.2 (2.8) 
Gender (% female) 64% 50% 
WASI intelligence quotient (IQ) 109.0 (9.1) 112.8 (11.6) 
Using antidepressants (% yes) 17% 20% 
self-report   
Beck Depression Inventory 
(pre) 23.7 (8.7) 23.2 (8.6) 
WHOQOL physical health (pre) 52.9 (18.7) 52.7 (19.5) 
WHOQOL psychological health 
(pre) 37.7 (14.3) 42.7 (14.6) 
WHOQOL social relationships 
(pre) 35.7 (25.4) 33.0 (21.9) 
WHOQOL environment (pre) 51.9 (21.7) 54.9 (21.1) 
DSM-IV clinician scales   
CAPS total (pre) 66.3 (15.2) 71.4 (15.0) 
CAPS total (post, completers) 29.6 (21.2) 64.2 (21.8) 
CAPS re-experiencing (pre) 17.5 (6.4) 18.7 (6.0) 
CAPS avoidance (pre) 27.0 (7.9) 28.8 (8.9) 
CAPS hyperarousal (pre) 21.9 (6.3) 23.9 (4.9) 
CAPS dissociation 1.8 (2.6) 1.5 (2.7)   
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Table S5: Demographic and clinical characteristics of participants in Study 2 who did 
or did not undergo spTMS/EEG (pooling across healthy and PTSD groups). Shown 
are means and (standard deviations). 
 
 Study 2 
  No spTMS/EEG (N=121) Yes spTMS/EEG (N=124) 
Age (yr) 32.1 (6.9) 33.3 (7.9) 
Education (yr) 15.1 (2.0) 15.5 (2.2) 
Gender (% female) 14.9% 8.1% 
WASI intelligence quotient (IQ) 105.6 (11.0) 106.1 (12.6) 
Using medications (% yes) 19% 16% 
Handedness (% right handed) 91% 88% 
self-report   
Beck Depression Inventory 11.3 (11.9) 12.5 (12.3) 
WHOQOL physical health 71.2 (17.9) 70.8 (18.6) 
WHOQOL psychological 
health 63.7 (19.5) 59.6 (21.2) 
WHOQOL social relationships 59.6 (22.0) 57.4 (25.5) 
WHOQOL environment 66.0 (18.2) 65.3 (16.7) 
DSM-5 clinician scales   
CAPS total 15.6 (13.8) 16.4 (15.2) 
CAPS re-experiencing 3.8 (3.9) 3.7 (3.9) 
CAPS avoidance 1.7 (1.9) 2.3 (2.3) 
CAPS hyperarousal 5.0 (5.6) 5.0 (5.7) 
CAPS negative cognitions 5.2 (4.2) 5.5 (4.8) 
 
